<?xml version="1.0" encoding="UTF-8"?>
<p>Based on these data, we moved forward with testing AAV-vectored approaches to long-term delivery of mAbs in vivo. Given the vector availability at the time, antibody Fc in AAV constructs did not include the LS mutation.</p>
